- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00265317
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone (SUN1058)
January 31, 2013 updated by: Pfizer
Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
162
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Pfizer Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Pfizer Investigational Site
-
-
-
-
-
Budapest, Hungary, 1525
- Pfizer Investigational Site
-
Torokbalint, Hungary, 2045
- Pfizer Investigational Site
-
-
-
-
-
Genova, Italy, 16132
- Pfizer Investigational Site
-
Monteforte Irpino, AV, Italy, 83024
- Pfizer Investigational Site
-
-
-
-
-
Amsterdam, Netherlands, 1066 CX
- Pfizer Investigational Site
-
Groningen, Netherlands, 9713 GZ
- Pfizer Investigational Site
-
-
-
-
-
Bydgoszcz, Poland, 85-796
- Pfizer Investigational Site
-
Gdansk, Poland, 80-952
- Pfizer Investigational Site
-
-
-
-
-
Bucuresti, Romania, 30171
- Pfizer Investigational Site
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400015
- Pfizer Investigational Site
-
-
Sector 2
-
Bucuresti, Sector 2, Romania, 022328
- Pfizer Investigational Site
-
-
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35294
- Pfizer Investigational Site
-
Mobile, Alabama, United States, 36604
- Pfizer Investigational Site
-
-
California
-
Antioch, California, United States, 94531
- Pfizer Investigational Site
-
Palm Springs, California, United States, 92262-4885
- Pfizer Investigational Site
-
Pleasant Hill, California, United States, 94523
- Pfizer Investigational Site
-
San Leandro, California, United States, 94578
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Pfizer Investigational Site
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Pfizer Investigational Site
-
St. Louis, Missouri, United States, 63110
- Pfizer Investigational Site
-
St. Louis, Missouri, United States, 63110-1094
- Pfizer Investigational Site
-
St. Peters, Missouri, United States, 63376
- Pfizer Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7600
- Pfizer Investigational Site
-
Clinton, North Carolina, United States, 28328
- Pfizer Investigational Site
-
Goldsboro, North Carolina, United States, 27534
- Pfizer Investigational Site
-
Wilson, North Carolina, United States, 27893
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with locally advanced/metastatic non-small cell lung cancer
- Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen
Exclusion Criteria:
- Prior treatment with any receptor tyrosine kinase inhibitors, Vascular endothelial growth factor (VEGF) inhibitors or other angiogenic inhibitors
- History of or known brain metastases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: B
|
erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
|
Experimental: A
|
erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS=time from randomization date to date of first documentation of progressive disease (PD; defined as greater than or equal to [≥]20% increase in sum of longest dimensions of target lesions taking as a reference smallest sum of longest dimensions recorded since first dose or appearance of ≥1 new lesions) or death on-study due to any cause, whichever occurred first based on third party independent imaging review laboratory assessment.
PFS calculated as (first event date minus randomization date plus 1) divided by 7.02.
Used 7.02 days as it equals 365 days per year divided by 52 weeks per year.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Objective Response
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Objective Response Rate (ORR)=participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST,Version 1.0) based on third party independent imaging review laboratory assessment.
A CR was defined as the disappearance of all target lesions that persisted on repeat imaging study at least 4 weeks after initial documentation of response.
A PR was defined as a ≥30% decrease in sum of longest dimensions of target lesions taking as a reference the baseline sum longest dimensions.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Time to Tumor Progression (TTP)
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
TTP was defined as the time from date of randomization to first documentation of PD based on third party independent imaging review laboratory assessment.
TTP was calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Duration of Response (DR)
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
DR was defined as time from first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of PD or death on-study due to any cause, whichever occurred first.
DR was calculated as (first date of PD or death minus first date of CR or PR that was subsequently confirmed plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Overall Survival (OS)
Time Frame: From randomization until death (up to Month 17)
|
OS was defined as time from date of randomization to date of death due to any cause.
OS was calculated as (date of death minus date of randomization plus 1) divided by 30.4.
For participants still alive at the time of analysis, OS time was censored on last date that participants were known to be alive.
|
From randomization until death (up to Month 17)
|
Percentage of Participants Surviving at 1 Year
Time Frame: From randomization until death (up until Month 17)
|
Percentage of participants alive at 1 year after date of first administration of study medication.
|
From randomization until death (up until Month 17)
|
Area Under the Curve From Time Zero to 24 Hours [AUC(0-24)] of Erlotinib
Time Frame: Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
AUC0-24=Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours (0-24) of erlotinib
|
Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
AUC(0-24) of Sunitinib
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
AUC0-24=Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours (0-24) of sunitinib
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
AUC(0-24) of SU-012662 (Metabolite of Sunitinib)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
AUC0-24=Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours (0-24) of SU-012662 (metabolite of sunitinib)
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
AUC(0-24) of Total Drug (Sunitinib + SU-012662)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
AUC0-24=Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours (0-24) of total drug (sunitinib + SU-012662)
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
Maximum Observed Plasma Concentration (Cmax) of Erlotinib
Time Frame: Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
|
Cmax of Sunitinib
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
|
Cmax of SU-012662 (Metabolite of Sunitinib)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
|
Cmax of Total Drug (Sunitinib + SU-012662)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) for Erlotinib
Time Frame: Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose; predose on Days 22 and 23 (Cycle 1)
|
AUC (0-inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf) for erlotinib.
It is obtained from AUC from time zero (pre-dose) to last quantifiable concentration(AUC[0-t]) plus AUC from time last quantifiable concentration extrapolated infinite time (AUC[t-inf])
|
Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose; predose on Days 22 and 23 (Cycle 1)
|
AUC(0-inf) for Sunitinib
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose; predose on Days 15, 16, and 17 (Cycle 1)
|
AUC (0 - inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf) for sunitinib.
It is obtained from AUC(0-t) plus AUC(t-inf)
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose; predose on Days 15, 16, and 17 (Cycle 1)
|
AUC(0-inf) for SU-012662 (Metabolite of Sunitinib)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose; predose on Days 15, 16, and 17 (Cycle 1)
|
AUC(0-inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf) for SU-012662 (metabolite of sunitinib).
It is obtained from AUC(0-t) plus AUC(t-inf)
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose; predose on Days 15, 16, and 17 (Cycle 1)
|
AUC(0-inf) for Total Drug (Sunitinib + SU-012662)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose; predose on Days 15, 16, and 17 (Cycle 1)
|
AUC(0-inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf) for total drug (sunitinib + SU-012662).
It is obtained from AUC(0-t) plus AUC(t-inf)
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose; predose on Days 15, 16, and 17 (Cycle 1)
|
Plasma Decay Half-life (t1/2) of Erlotinib
Time Frame: Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
|
Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
Plasma Decay Half-life (t1/2) of Sunitinib
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Erlotinib Clearance at Steady State After Oral Administration (CL/F)
Time Frame: Day 15 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
Day 15 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
|
Sunitinib Clearance at Steady State After Oral Administration (CL/F)
Time Frame: Day 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Day 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Erlotinib
Time Frame: Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
Days 1 and 22 (Cycle 1) at 0, 1, 2, 4, 6, 8, and 24 hours postdose
|
|
Tmax for Sunitinib
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
|
Tmax for SU-012662 (Metabolite of Sunitinib)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
|
Tmax for Total Drug (Sunitinib + SU-012662)
Time Frame: Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
Days 1 and 15 of Cycle 1 at 0, 1, 2, 4, 6, 8, 24 and 48 hours postdose
|
|
Dose-Corrected Observed Plasma Trough Concentrations (Ctrough) for Erlotinib on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)
Time Frame: predose Day 1 (Cycles 3-13); predose Day 1 (Cycles 1-18)
|
Ctrough = plasma concentration of erlotinib prior to study drug administration.
Dose correction was made to the initial intended dose in Cycle 1. Assessed in the Original and Amended Lead-In (Arms A and B) Cohorts predose on Day 1 (Cycles 3-13) and in the Randomized Cohort (Sunitinib + Erlotinib treatment group only) predose on Day 1 of Cycles 1-18.
|
predose Day 1 (Cycles 3-13); predose Day 1 (Cycles 1-18)
|
Dose-Corrected Ctrough for Erlotinib on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)
Time Frame: predose Day 15 (Cycle1); predose Day 1 (Cycle 3); predose Day 1 (Cycles 1-18)
|
Ctrough = plasma concentration of erlotinib prior to study drug administration.
Dose correction was made to the initial intended dose in Cycle 1. Assessed in the Original Cohort predose on Day 15 (Cycle 1, Time Zero) and Day 1 (Cycle 3), in the Amended Lead-In Cohort (Arms A and B) predose on Day 1 (Cycle 3) and in the Randomized Cohort (Sunitinib + Erlotinib treatment group only) predose on Day 1 of Cycles 1-18.
|
predose Day 15 (Cycle1); predose Day 1 (Cycle 3); predose Day 1 (Cycles 1-18)
|
Dose-Corrected Ctrough for Sunitinib on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)
Time Frame: predose Day 1 (Cycles 3-13); predose Day 1 (Cycles 1-18)
|
Ctrough = plasma concentration of sunitinib prior to study drug administration.
Dose correction was made to the initial intended dose in Cycle 1. Assessed in the Original and Amended Lead-In (Arms A and B) Cohorts predose on Day 1 (Cycles 3-13) and in the Randomized Cohort (Sunitinib + Erlotinib treatment group only) predose on Day 1 of Cycles 1-18.
|
predose Day 1 (Cycles 3-13); predose Day 1 (Cycles 1-18)
|
Dose-Corrected Ctrough for Sunitinib on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)
Time Frame: predose Day 15 (Cycle 1) and Day 1 (Cycle 3); predose Day 1 (Cycle 3); predose Day 1 (Cycles 1-18)
|
Ctrough = plasma concentration of sunitinib prior to study drug administration.
Dose correction was made to the initial intended dose in Cycle 1. Assessed in the Original Cohort predose on Day 15 (Cycle 1, Time Zero) and Day 1 (Cycle 3), in the Amended Lead-In Cohort (Arms A and B) predose on Day 1 (Cycle 3) and in the Randomized Cohort (Sunitinib + Erlotinib treatment group only) predose on Day 1 of Cycles 1-18.
|
predose Day 15 (Cycle 1) and Day 1 (Cycle 3); predose Day 1 (Cycle 3); predose Day 1 (Cycles 1-18)
|
Dose-Corrected Ctrough for SU-012662 (Metabolite of Sunitinib) on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)
Time Frame: predose Day 1 (Cycles 3-13); predose Day 1 (Cycles 1-18)
|
Ctrough = plasma concentration of SU-012662 prior to study drug administration.
Dose correction was made to the initial intended dose in Cycle 1. Assessed in the Original and Amended Lead-In (Arms A and B) Cohorts predose on Day 1 (Cycles 3-13) and in the Randomized Cohort (Sunitinib + Erlotinib treatment group only) predose on Day 1 of Cycles 1-18.
|
predose Day 1 (Cycles 3-13); predose Day 1 (Cycles 1-18)
|
Dose-Corrected Ctrough for SU-012662 (Metabolite of Sunitinib) on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)
Time Frame: predose Day 15 (Cycle 1) and Day 1 (Cycle 3); predose Day 1 (Cycle 3); predose Day 1 (Cycles 1-18)
|
Ctrough = plasma concentration of SU-012662 prior to study drug administration.
Dose correction was made to the initial intended dose in Cycle 1. Assessed in the Original Cohort predose on Day 15 (Cycle 1, Time Zero) and Day 1 (Cycle 3), in the Amended Lead-In Cohort (Arms A and B) predose on Day 1 (Cycle 3) and in the Randomized Cohort (Sunitinib + Erlotinib treatment group only) predose on Day 1 of Cycles 1-18.
|
predose Day 15 (Cycle 1) and Day 1 (Cycle 3); predose Day 1 (Cycle 3); predose Day 1 (Cycles 1-18)
|
Percentage of Participants With Epidermal Growth Factor Receptor (EGFR) Expression by Immunohistochemistry (IHC) Using 0 Percent [%] Cutoff
Time Frame: Baseline
|
Percentage of participants with EGFR expression by IHC using a 0% cutoff; Reported as positive, negative, or unmeasured (where positive was greater than 0% of cells demonstrating membranous staining for EGFR).
Correlative analysis of EGFR expression was conducted using tumor biopsy samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
|
Baseline
|
PFS in Subgroups That Were Defined by EGFR Expression (Using 0% Cutoff)
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS defined as time in weeks from date of randomization to date of first documentation of PD or death on-study due to any cause, whichever occurred first, in the following subgroups: positive, negative, or unmeasured EGFR expression.
EGFR expression was analyzed using a 0% cutoff where positive was greater than 0% of cells demonstrating membranous staining for EGFR.
PFS calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Percentage of Participants With EGFR Expression by IHC (Using 10% Cutoff)
Time Frame: Baseline
|
Percentage of participants with EGFR Expression by IHC using a 10% cutoff; Reported as positive (positive values were defined as being greater than 10% of cells demonstrating membranous staining for EGFR), negative, or unmeasured.
Correlative analysis of EGFR expression was conducted using tumor biopsy samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
|
Baseline
|
PFS in Subgroups That Were Defined by EGFR Expression (Using 10% Cutoff)
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS defined as time in weeks from date of randomization to date of first documentation of PD or death on-study due to any cause, whichever occurred first, in the following subgroups: positive, negative, or unmeasured EGFR expression.
EGFR expression was analyzed using a 10% cutoff where positive was greater than 10% of cells demonstrating membranous staining for EGFR.
PFS calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Percentage of Participants With EGFR Gene Copy Number Increase
Time Frame: Baseline
|
The number of copies corresponding to exon 19 of the EGFR gene was determined by real-time quantitative polymerase chain reaction (PCR).
The percentage of participants with EGFR Gene Copy Number Increase (defined as greater than 4 copies) was determined using deoxyribonucleic acid (DNA) from tumor biopsy samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
Reported as yes, no or unmeasured.
|
Baseline
|
PFS in Subgroups That Were Defined by EGFR Gene Copy Number Increase
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS, defined as time from date of randomization to the date of the first documentation of PD or death on-study due to any cause, whichever occurred first, in subgroups that were defined by EGFR gene copy number increase (reported as yes, no, or unmeasured).
The number of copies corresponding to exon 19 of the EGFR gene was determined and an increase was defined as greater than 4 copies.
PFS was calculated as (first event date minus randomization date plus 1)/7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Percentage of Participants With EGFR Gene Amplification
Time Frame: Baseline
|
The percentage of participants with EGFR gene amplification (defined as greater than 15) was determined and reported as yes, no, or unmeasured.
Correlative analysis of EGFR gene amplification was conducted using tumor biopsy samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
|
Baseline
|
PFS in Subgroups That Were Defined by EGFR Gene Amplification
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS, defined as time from date of randomization to date of first documentation of PD or death on-study due to any cause, whichever occurred first, in subgroups that were defined by EGFR gene amplification (defined as greater than 15) and reported as no or unmeasured.
PFS was calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Percentage of Participants With EGFR Gene Mutation
Time Frame: Baseline
|
Mutations in exons 18 through 21 of the EGFR gene were analyzed by high-performance liquid chromatography using DNA from tumor biopsy samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
The percentage of participants with EGFR mutations categorized as mutated, wild type or indeterminate was reported.
|
Baseline
|
PFS in Subgroups That Were Defined by EGFR Gene Mutation
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS, defined as time from date of randomization to date of first documentation of PD or to death on-study due to any cause, whichever occurred first, in subgroups that were defined by EGFR gene mutation (reported as mutated, wild type, or indeterminate).
PFS was calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Percentage of Participants With KRAS (V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog) Gene Mutations
Time Frame: Baseline
|
Mutations in exons 2-3 of the KRAS gene (including codons 12, 13, and 61) were analyzed by high-performance liquid chromatography using DNA from tumor biopsy samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
The percentage of participants with KRAS mutations categorized as mutated, wild type or indeterminate was reported.
|
Baseline
|
PFS in Subgroups That Were Defined by KRAS Gene Mutation
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS, defined as time from date of randomization to date of first documentation of PD or death on-study due to any cause, whichever occurred first, in subgroups that were defined by KRAS gene mutation (reported as mutated, wild type, or indeterminate).
PFS was calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Percentage of Participants With Germline Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Polymorphisms
Time Frame: Baseline
|
Blood samples were collected at baseline for multiplex reverse transcription (RT) analysis of genes expressing proteins that are targets of sunitinib or involved in angiogenesis or tumor growth to determine expression levels.
Percentage of participants with germline VEGFR2 single nucleotide polymorphisms (SNPs) was reported for the following genotype frequencies: homozygous C alleles (C/C), T alleles (T/T), G alleles (G/G), or A alleles (A/A), and the following heterozygous genotypes C/T, G/T, T/A, and G/A.
|
Baseline
|
PFS in Subgroups That Were Defined by Germline VEGFR2 Polymorphisms
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS, defined as time from date of randomization to date of first documentation of PD or death on-study due to any cause, whichever occurred first, in subgroups that were defined by VEGFR2 polymorphisms.
PFS was calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Overall Survival (OS) in Subgroups That Were Defined by Germline VEGFR2 Polymorphisms
Time Frame: From randomization until death (up to Month 17)
|
OS, defined as time from date of randomization to date of death due to any cause, in subgroups that were defined by VEGFR2 polymorphisms.
OS was calculated as (date of death minus date of randomization plus 1) divided by 30.4.
|
From randomization until death (up to Month 17)
|
Percentage of Participants With Germline Platelet-derived Growth Factor Receptor Beta (PDGFRB) Polymorphisms
Time Frame: Baseline
|
Blood samples were collected at baseline for multiplex RT analysis of genes expressing proteins that are targets of sunitinib or involved in angiogenesis or tumor growth to determine expression levels.
Percentage of participants with germline PDGFRB SNPs was reported for the following genotype frequencies: homozygous C alleles (C/C), T alleles (T/T), G alleles (G/G), or A alleles (A/A), and the following heterozygous genotypes C/T, A/T, A/G, T/C, T/G, G/C, C/A and G/A.
|
Baseline
|
PFS in Subgroups That Were Defined by Germline PDGFRB Polymorphisms
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS, defined as time from date of randomization to date of first documentation of PD or death on-study due to any cause, whichever occurred first, in subgroups that were defined by PDGFRB polymorphisms.
PFS was calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
OS in Subgroups That Were Defined by Germline PDGFRB Polymorphisms
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
OS, defined as time from date of randomization to date of death due to any cause, in subgroups that were defined by PDGFRB polymorphisms.
OS was calculated as (date of death minus date of randomization plus 1) divided by 30.4.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Percentage of Participants by Tumor VEGFR Mutation
Time Frame: Baseline
|
Percentage of participants with VEGFR mutations in DNA from tumor samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
|
Baseline
|
Correlation of Polymorphisms in Stem Cell Factor Receptor (c-Kit), FMS-like Tyrosine Kinase 3 Receptor (FLT-3), and c-FMS With Blood Counts
Time Frame: Baseline (Day 1, Cycle 1)
|
A blood sample (6 mL) was collected before on-study treatment and was used to isolate DNA.
These samples were not anonymized.
Correlation was investigated by the percentage of participants with anemia (based on hemoglobin count), neutropenia (based on neutrophil count) and thrombocytopenia (based on platelet count) endpoints and genetic variation as measured by c-KIT, FLT-3, and c-FMS was to be analyzed.
|
Baseline (Day 1, Cycle 1)
|
Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile
Time Frame: Baseline
|
Includes colony-stimulating factor 1 receptor (CSF-1R), PDGFRalpha, PDGFRbeta, vascular endothelial growth factor (VEGF), VEGF C (VEGF-C), VEGF receptor 1 (VEGFR1), VEGF receptor 2 (VEGFR2), VEGF receptor 3 (VEGFR3), fibroblast growth factor (FGF), FLT-3, KIT (stem cell factor receptor), and RET (rearranged during transfection).
Correlative analysis was conducted using tumor biopsy samples collected at the time of initial diagnosis (preferred) or at the time of most recent recurrence/progression, although any time was acceptable.
|
Baseline
|
PFS in Subgroups That Were Defined by RNA Expression Profile
Time Frame: From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
PFS, defined as time from date of randomization to date of first documentation of PD or death on-study due to any cause, whichever occurred first, in subgroups that were defined by RNA Gene expression (CSF-1R, PDGFRalpha, PDGFRbeta, VEGF, VEGF-C, VEGFR1, VEGFR2, VEGFR3, FGF, FLT-3, KIT, and RET).
PFS was calculated as (first event date minus randomization date plus 1) divided by 7.02.
|
From randomization to Weeks 8 and 12, then every 8 weeks until disease progression or death (up to Month 17)
|
Health Related Quality of Life (HRQoL) and Lung Cancer Related Symptoms as Assessed With European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) Score
Time Frame: Baseline (Cycle [C] 1, Day [D] 1) to Cycle 18, Day 1
|
EORTC QLQ-C30: self-administered questionnaire assessing global health status/quality of life (QoL), functional domains (physical, role, cognitive, emotional, and social), symptom scales/items (fatigue, pain, nausea and vomiting, dyspnea, insomnia, loss of appetite, constipation, and diarrhea), and financial difficulties.
Recall period: past week; response range: not at all (1) to very much (4); global/QoL range: very poor (1) to excellent (7).
Scale score range: 0 to 100.
Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms.
|
Baseline (Cycle [C] 1, Day [D] 1) to Cycle 18, Day 1
|
EORTC-QLQ-C30 Lung Cancer Module (LC13) Score
Time Frame: Baseline (Cycle 1 [Day 1]) to Cycle 18 (Day 1)
|
The EORTC-QLQ-C30 LC13 is a self-administered questionnaire assessing specific lung cancer disease related symptoms (dyspnea, coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in the chest, arm/shoulder or other parts of the body).
Recall period: past week; response range: not at all (1) to very much (4).
Scale score range: 0 to 100.
Higher symptom score = greater degree of symptoms.
|
Baseline (Cycle 1 [Day 1]) to Cycle 18 (Day 1)
|
Number of Participants With Blood Pressure (BP) Greater Than 150/100 Millimeters of Mercury (mmHg)
Time Frame: Randomization up until Month 17
|
Systolic/diastolic BP measured in triplicate (separated by approximately 2 minutes [min]) using validated electronic device (same device for all measurements), recorded to nearest mmHg.
Dominant arm used (same one each time) with appropriate cuff size encircling at least 80% of arm.
BP measured after 5 min rest and before invasive procedures, while seated in a chair with back supported, arms bared, supported at heart level.
No smoking or caffeine use allowed during 30 min before measurement.
Number of participants with systolic BP >150 mmHg/diastolic BP >100 mmHg at any timepoint postbaseline.
|
Randomization up until Month 17
|
Number of Participants With BP Greater Than 200/110 mmHg
Time Frame: Randomization up until Month 17
|
Systolic/diastolic BP measured in triplicate (separated by approximately 2 minutes [min]) using validated electronic device (same device for all measurements), recorded to nearest mmHg.
Dominant arm used (same one each time) with appropriate cuff size encircling at least 80% of arm.
BP measured after 5 min rest and before invasive procedures, while seated in a chair with back supported, arms bared, supported at heart level.
No smoking or caffeine use allowed during 30 min before measurement.
Number of participants with systolic BP >150 mmHg/diastolic BP >100 mmHg at any timepoint postbaseline.
|
Randomization up until Month 17
|
Number of Participants on Anti-hypertensive Medications
Time Frame: Randomization to Day 28 of Cycle 18
|
Number of participants with BP greater than 150/100 mmHg or 200/110 mmHg who were treated with anti-hypertensive medications.
|
Randomization to Day 28 of Cycle 18
|
Plasma Concentration of VEGF-C at Baseline
Time Frame: Baseline (Cycle 1, Day 1)
|
Baseline (Cycle 1, Day 1)
|
|
Plasma Concentration of Soluble VEGFR-2 at Baseline
Time Frame: Baseline (Cycle 1, Day 1)
|
Baseline (Cycle 1, Day 1)
|
|
Plasma Concentration of Soluble VEGFR-3 at Baseline
Time Frame: Baseline (Cycle 1, Day 1)
|
Baseline (Cycle 1, Day 1)
|
|
Plasma Concentration of Soluble KIT (sKIT) at Baseline
Time Frame: Baseline (Cycle 1, Day 1)
|
Baseline (Cycle 1, Day 1)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VEGF-C Ratio to Baseline at Each Timepoint
Time Frame: Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
Plasma VEGF-C concentration at each time point divided by VEGF-C concentration at baseline (ratio to baseline)
|
Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
VEGFR-2 Ratio to Baseline at Each Timepoint
Time Frame: Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
Plasma VEGFR-2 concentration at each time point divided by VEGFR-2 concentration at baseline (ratio to baseline)
|
Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
VEGFR-3 Ratio to Baseline at Each Timepoint
Time Frame: Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
Plasma VEGFR-3 concentration at each time point divided by VEGFR-3 concentration at baseline (ratio to baseline)
|
Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
sKIT Ratio to Baseline at Each Timepoint
Time Frame: Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
Plasma sKIT concentration at each time point divided by sKIT concentration at baseline (ratio to baseline)
|
Baseline to Cycle 2 (Day 1) and Cycle 3 (Day 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Actual)
January 1, 2010
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
December 12, 2005
First Submitted That Met QC Criteria
December 12, 2005
First Posted (Estimate)
December 14, 2005
Study Record Updates
Last Update Posted (Estimate)
February 6, 2013
Last Update Submitted That Met QC Criteria
January 31, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Sunitinib
Other Study ID Numbers
- A6181058
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on erlotinib
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California and other collaboratorsCompleted
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
Grupo de Investigación Clínica en Oncología RadioterapiaCompletedSquamous Cell Carcinoma of the Head and NeckSpain
-
Kyowa Kirin Co., Ltd.TerminatedNon-small-cell Lung CancerJapan
-
Merck Sharp & Dohme LLCCompleted
-
Duke UniversityBristol-Myers Squibb; Genentech, Inc.Completed